TURNSTONE BIOLOGICS CORP.
Profile
Company Names
TURNSTONE BIOLOGICS CORP.
Addresses
920 BROADWAY, 16TH FLOOR, NEW YORK, NY 10010
Phone Numbers
347-897-5988
Entity Type:
CORPORATION
Industry:
BIOTECHNOLOGY
Year Incorporated:
2018
State Incorporated:
DELAWARE
Total Amount Raised:
$122,099,966.00
Number of Funding Rounds:
2
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
2
2021-06-29
$79,999,979.00
$79,999,979.00
$0.00
Equity
1
2019-01-04
$42,099,987.00
$42,099,987.00
$0.00
Equity
People
First Name
Middle Name
Last Name
Titles
Related Companies
JEREL
DAVIS
DIRECTOR
CHANRX CORP.
| LAGUNA PHARMACEUTICALS, INC.
| INCEPTION IBD, INC.
| TRAVUS THERAPEUTICS, INC.
| VERSANT VENTURE CAPITAL VI, L.P.
| MISTRAL THERAPEUTICS, INC.
| VERSANT VOYAGEURS I FEEDER, L.P.
| VERSANT VENTURE CAPITAL VII, L.P.
| TURNSTONE BIOLOGICS CORP.
| NORTHERN MOSAIC LP
| VERSANT VOYAGEURS I, L.P.
| VERSANT VOYAGEURS I PARALLEL, L.P.
| CHINOOK THERAPEUTICS U.S., INC.
| VENTUS THERAPEUTICS U.S., INC.
| TENTARIX BIOTHERAPEUTICS, LP
| RAYZEBIO, INC.
| GRAPHITE BIO, INC.
| VERSANT VANTAGE II, L.P.
| VERSANT VOYAGEURS II, L.P.
| VERSANT VOYAGEURS II (CANADA), L.P.
| VERSANT VENTURE CAPITAL VIII, L.P.
| VERSANT VENTURE CAPITAL VIII (CANADA), L.P.
| SANTA ANA BIO, INC.
| VERSANT VOYAGEURS III, L.P.
| VERSANT VOYAGEURS III (CANADA), L.P.
| VERSANT VANTAGE III, L.P.
| VERSANT VANTAGE III (CANADA), L.P.
| VERSANT VENTURE CAPITAL IX, L.P.
| VERSANT VENTURE CAPITAL IX (CANADA), L.P.
| FIREFLY BIO, INC.
| VERSANT VENTURE CAPITAL SPV I (SAB), L.P.
ROBERT
GOULD
DIRECTOR
RISHI
GUPTA
DIRECTOR
GELESIS INC
| SIENTRA, INC.
| AVITIDE, INC.
| SYMBIOMIX THERAPEUTICS, LLC
| DIMENSION THERAPEUTICS, INC.
| MEVES PHARMACEUTICALS, INC.
| ATTENUA, INC.
| TURNSTONE BIOLOGICS CORP.
| GOLDEN TEAK CAPITAL L.P.
| NEUROPACE INC
| VERONA PHARMA PLC
| CHARM THERAPEUTICS INC.
| DELFI DIAGNOSTICS, INC.
| AER THERAPEUTICS, INC.
| HELICORE BIOVENTURES I, INC.
| ENLIVEN THERAPEUTICS, INC.
| WILSHIRE SELECTIVE OPPORTUNITIES PROGRAM SPC - WILSOP SEGREGATED PORTFOLIO 5
JANE
HENDERSON
EXECUTIVE OFFICER
STEFAN
LARSON
DIRECTOR
PATRICK
MACHADO
DIRECTOR
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#

